AU2003272979B2 - 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles - Google Patents

2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles Download PDF

Info

Publication number
AU2003272979B2
AU2003272979B2 AU2003272979A AU2003272979A AU2003272979B2 AU 2003272979 B2 AU2003272979 B2 AU 2003272979B2 AU 2003272979 A AU2003272979 A AU 2003272979A AU 2003272979 A AU2003272979 A AU 2003272979A AU 2003272979 B2 AU2003272979 B2 AU 2003272979B2
Authority
AU
Australia
Prior art keywords
group
substituted
halogen
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003272979A
Other languages
English (en)
Other versions
AU2003272979A1 (en
Inventor
Yoshikazu Haraguchi
Takeshi Hasegawa
Hiroyuki Hashizume
Motohiro Itotani
Masanori Kawasaki
Makoto Komatsu
Hideaki Kuroda
Takeshi Kuroda
Makoto Matsumoto
Takayuki Matsuzaki
Shin Miyamura
Hirofumi Sasaki
Yuji Seike
Takumi Sumida
Kuninori Tai
Tatsuo Tomishige
Hidetsugu Tsubouchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2003272979A1 publication Critical patent/AU2003272979A1/en
Application granted granted Critical
Publication of AU2003272979B2 publication Critical patent/AU2003272979B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2003272979A 2002-10-11 2003-10-10 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles Expired AU2003272979B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11
JP2002-298259 2002-10-11
PCT/JP2003/013070 WO2004033463A1 (ja) 2002-10-11 2003-10-10 ２，３−ジヒドロ−６−ニトロイミダゾ[２，１−ｂ]オキサゾール化合物

Publications (2)

Publication Number Publication Date
AU2003272979A1 AU2003272979A1 (en) 2004-05-04
AU2003272979B2 true AU2003272979B2 (en) 2009-07-23

Family

ID=32089299

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003272979A Expired AU2003272979B2 (en) 2002-10-11 2003-10-10 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles

Country Status (26)

Country Link
US (1) US7262212B2 (https=)
EP (2) EP2570418A3 (https=)
JP (1) JP4186065B2 (https=)
KR (1) KR100723847B1 (https=)
CN (4) CN102532162B (https=)
AR (4) AR041198A1 (https=)
AU (1) AU2003272979B2 (https=)
BE (1) BE2014C053I2 (https=)
BR (1) BRPI0314344B8 (https=)
CA (1) CA2497569C (https=)
CY (2) CY1113578T1 (https=)
DK (1) DK1555267T3 (https=)
ES (1) ES2400179T3 (https=)
FR (1) FR14C0066I2 (https=)
HU (1) HUS1400046I1 (https=)
LU (1) LU92517I2 (https=)
MX (1) MXPA05003674A (https=)
MY (1) MY139244A (https=)
PL (3) PL404913A1 (https=)
PT (1) PT1555267E (https=)
RU (1) RU2326121C3 (https=)
SI (1) SI1555267T1 (https=)
TW (1) TWI347946B (https=)
UA (1) UA83200C2 (https=)
WO (1) WO2004033463A1 (https=)
ZA (1) ZA200501033B (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
MY145079A (en) 2002-10-15 2011-12-15 Otsuka Pharma Co Ltd 1-substituted-4-nitroimidazole compound and method for preparing the same
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
WO2005042542A1 (en) 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
US7485727B2 (en) 2004-03-31 2009-02-03 Nippon Soda Co., Ltd. Cyclic amine compound and pest control agent
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
EP1896453B1 (en) * 2005-06-20 2009-12-02 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
ES2355524T3 (es) * 2005-07-28 2011-03-28 Otsuka Pharmaceutical Co., Ltd. Composición farmacéutica que comprende los derivados de 2,3-dihidro-6-nitroimidazo[2,1-b]oxazol.
TW201233389A (en) * 2005-10-05 2012-08-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
US8338607B2 (en) 2005-10-06 2012-12-25 Nippon Soda Co., Ltd. Cyclic amine compounds and agents for pest control
TW200800268A (en) 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
US7750012B2 (en) 2005-12-21 2010-07-06 Decode Genetics Ehf Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
EP1986637A1 (en) * 2006-02-13 2008-11-05 Laboratoires Serono SA Sulfonamide derivatives for the treatment of bacterial infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
CA2678577A1 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
EP2183228B1 (en) * 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
PE20090595A1 (es) * 2007-08-15 2009-06-06 Glaxo Group Ltd Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
JP2011500634A (ja) * 2007-10-16 2011-01-06 グラクソ グループ リミテッド 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
US8598160B2 (en) * 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5538356B2 (ja) * 2008-03-18 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
CA2712613C (en) * 2008-03-26 2017-02-28 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
CL2009001059A1 (es) * 2008-05-01 2010-11-12 Boehringer Ingelheim Int Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
CA2723032A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
WO2010021409A1 (en) 2008-08-21 2010-02-25 Dynamit Nobel Gmbh Explosivstoff - Und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011002910A1 (en) 2009-07-01 2011-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011014774A1 (en) * 2009-07-31 2011-02-03 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
ES2530266T3 (es) * 2009-07-31 2015-02-27 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina y sus usos
US20120219500A1 (en) 2009-10-26 2012-08-30 Fujifilm Ri Pharma Co., Ltd. Diagnostic agent for infectious diseases
TW201200523A (en) * 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
PH12013500808A1 (en) 2010-11-02 2015-10-07 Boehringer Ingelheim Int Pharmaceutical combinations for the treatment of metabolic disorders
JP5916739B2 (ja) 2011-04-15 2016-05-11 大塚製薬株式会社 ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
JP6532457B2 (ja) 2013-10-04 2019-06-19 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ ６−ニトロ−２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾール及びこれらの調製方法
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
US9822126B1 (en) 2014-10-21 2017-11-21 Council Of Scientific & Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
CN107207532B (zh) * 2015-01-29 2019-07-30 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
JP6776226B2 (ja) * 2015-03-27 2020-10-28 大塚製薬株式会社 １−（４−ヒドロキシフェニル）−４−（４−トリフルオロメトキシフェノキシ）ピペリジン又はその塩の製造方法
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
JP6905506B2 (ja) 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
JP2019521175A (ja) * 2016-07-22 2019-07-25 メッドシャイン ディスカバリー インコーポレイテッド ニトロイミダゾール系化合物の結晶形、塩形およびその製造方法
CA3072838A1 (en) * 2017-08-16 2019-02-21 Glaxosmithkline Intellectual Property Development Limited Novel compounds
JP7522655B2 (ja) 2018-06-11 2024-07-25 大塚製薬株式会社 デラマニド含有組成物
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
CN119522100A (zh) 2022-07-29 2025-02-25 大塚制药株式会社 含有德拉马尼的固体分散体
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sehgal, R. J. et al (1981) J. Med. Chem. 24:601-604 *

Also Published As

Publication number Publication date
AR041198A1 (es) 2005-05-04
US20060094767A1 (en) 2006-05-04
MY139244A (en) 2009-09-30
EP1555267B1 (en) 2013-01-16
CN1705670A (zh) 2005-12-07
UA83200C2 (en) 2008-06-25
CY1113578T1 (el) 2016-06-22
HK1085463A1 (zh) 2006-08-25
TWI347946B (en) 2011-09-01
AU2003272979A1 (en) 2004-05-04
CN100366624C (zh) 2008-02-06
PT1555267E (pt) 2013-01-29
BR0314344A (pt) 2005-07-12
PL217919B1 (pl) 2014-09-30
CN102532162A (zh) 2012-07-04
RU2005114017A (ru) 2006-01-20
SI1555267T1 (sl) 2013-05-31
KR100723847B1 (ko) 2007-05-31
EP2570418A3 (en) 2013-07-03
RU2326121C2 (ru) 2008-06-10
PL409525A1 (pl) 2014-11-10
MXPA05003674A (es) 2005-06-08
PL376157A1 (en) 2005-12-27
AR089950A2 (es) 2014-10-01
CN101172981A (zh) 2008-05-07
FR14C0066I1 (https=) 2014-10-17
CY2014041I2 (el) 2016-07-27
JP2004149527A (ja) 2004-05-27
JP4186065B2 (ja) 2008-11-26
BE2014C053I2 (https=) 2022-08-30
AR086485A2 (es) 2013-12-18
PL404913A1 (pl) 2013-09-30
CA2497569A1 (en) 2004-04-22
US7262212B2 (en) 2007-08-28
LU92517I2 (fr) 2014-10-13
CY2014041I1 (el) 2016-07-27
BRPI0314344B1 (pt) 2019-11-26
HUS1400046I1 (hu) 2017-04-28
RU2326121C3 (ru) 2021-09-17
WO2004033463A1 (ja) 2004-04-22
ES2400179T3 (es) 2013-04-08
CN101255170A (zh) 2008-09-03
EP2570418A2 (en) 2013-03-20
AR091771A2 (es) 2015-02-25
KR20050061473A (ko) 2005-06-22
CN102532162B (zh) 2015-05-27
FR14C0066I2 (fr) 2015-05-22
CA2497569C (en) 2011-05-24
BRPI0314344B8 (pt) 2021-05-25
TW200420568A (en) 2004-10-16
ZA200501033B (en) 2006-06-28
EP1555267A1 (en) 2005-07-20
HK1171018A1 (en) 2013-03-15
DK1555267T3 (da) 2013-02-11
EP1555267A4 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
AU2003272979B2 (en) 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
JP2004149527A5 (https=)
JP2005330266A5 (https=)
CN100540538C (zh) 高传导率钙-活化k通道开启剂
EP1954683B1 (en) 2-(phenyl or heterocyclyl)-1h-phenanthro(9,10-d)imidazoles as mpges-1 inhibitors
Kale et al. Recent developments in benzotriazole methodology for construction of pharmacologically important heterocyclic skeletons
US11345694B2 (en) Antibacterial compounds
PE20060609A1 (es) Derivados de quinuclidinas como antagonistas del receptor muscarinico (m3)
BRPI0413233A (pt) novos compostos
IL97313A (en) Substituted indoles, processes for preparing them, and compositions containing them, for reduction of intraocular pressure, and relief on pain and of rheumatic and inflammatory conditions.
US20240376105A1 (en) Heterocyclic glp-1 agonists
TW200418848A (en) Compounds
JP2007535520A (ja) 抗腫瘍作用を有するインドール及びアザインドール誘導体
WO2016141258A1 (en) Sterol regulatory element-binding proteins (srebps) inhibitors
Riego et al. Directly linked polyazoles: important moieties in natural products
NO20070977L (no) Dobbel NK1/Nk3 antagonister mot schizofreni
JP2010525024A5 (https=)
NO20055655D0 (no) Anvendelse av azetidinkarboksamidderivater i terapi
AU2008216106C1 (en) Cancer treatment method
CN101679454A (zh) 治疗细菌感染的抗菌杂环化合物
AR045791A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
JP2010519278A5 (https=)
PE20090112A1 (es) Derivados de indol como agonistas del receptor de canabinoides cb1
CN110698432A (zh) 苯甲基哌嗪类化合物及其制备方法和在抗病毒中的应用
JP2011518843A5 (https=)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired